Recruiting
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
NCT06838910
- Conditions
- Hemic and Lymphatic Diseases, Lymphatic Diseases, Neoplasms, +7 more
- Locations
-
- The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China